Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Amneal Pharmaceuticals, Inc is a drug manufacturers—specialty & generic business based in the US. Amneal Pharmaceuticals shares (AMRX) are listed on the NYSE and all prices are listed in US Dollars. Amneal Pharmaceuticals employs 5,500 staff and has a trailing 12-month revenue of around USD$1.7 billion.
|Latest market close||USD$4.08|
|52-week range||USD$2.4 - USD$5.79|
|50-day moving average||USD$4.1656|
|200-day moving average||USD$4.2288|
|Wall St. target price||USD$4.35|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.522|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||2.51%|
|1 month (2020-11-06)||-1.21%|
|3 months (2020-09-04)||11.78%|
|6 months (2020-06-05)||-17.58%|
|1 year (2019-12-05)||9.97%|
|2 years (2018-12-04)||-76.91%|
|3 years (2017-12-05)||-75.42%|
|5 years (2015-12-04)||-90.77%|
Valuing Amneal Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amneal Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amneal Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$343 million.
The EBITDA is a measure of a Amneal Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$1.7 billion|
|Operating margin TTM||6.85%|
|Gross profit TTM||USD$496.9 million|
|Return on assets TTM||1.79%|
|Return on equity TTM||-58.39%|
|Market capitalisation||USD$759.8 million|
TTM: trailing 12 months
There are currently 7.2 million Amneal Pharmaceuticals shares held short by investors – that's known as Amneal Pharmaceuticals's "short interest". This figure is 3.7% up from 6.9 million last month.
There are a few different ways that this level of interest in shorting Amneal Pharmaceuticals shares can be evaluated.
Amneal Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Amneal Pharmaceuticals shares currently shorted divided by the average quantity of Amneal Pharmaceuticals shares traded daily (recently around 959895.44846051). Amneal Pharmaceuticals's SIR currently stands at 7.47. In other words for every 100,000 Amneal Pharmaceuticals shares traded daily on the market, roughly 7470 shares are currently held short.
However Amneal Pharmaceuticals's short interest can also be evaluated against the total number of Amneal Pharmaceuticals shares, or, against the total number of tradable Amneal Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amneal Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Amneal Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0864% of the tradable shares (for every 100,000 tradable Amneal Pharmaceuticals shares, roughly 86 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Amneal Pharmaceuticals.
Find out more about how you can short Amneal Pharmaceuticals stock.
We're not expecting Amneal Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Amneal Pharmaceuticals's shares have ranged in value from as little as $2.4 up to $5.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Amneal Pharmaceuticals's is 1.4867. This would suggest that Amneal Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It has operations in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.